BeOne Medicines AG banner

Intrinsic Value

The intrinsic value of BeOne Medicines AG (6160) under the Base Case is HKD per share. Compared with the current market price of 247.4 HKD, the stock appears .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

BeOne Medicines AG Intrinsic Value

What one share is worth in the bear, base and bull cases.

Create a free account · No card needed

Do our valuations actually work? See backtest results .

Alert me when BeOne Medicines AG is below its intrinsic value
Today Hidden ·
BeOne Medicines AG Valuation History

Intrinsic value next to the price over the past 5 years.

Create a free account · No card needed

Alternatives to BeOne Medicines AG

Fundamental Analysis

What BeOne Medicines Does

Biotechnology Health Care

BeiGene is a cancer drug company that discovers, develops, manufactures, and sells medicines for oncology. Its best-known products are targeted therapies and immunotherapies used to treat different kinds of blood cancers and solid tumors. The company also runs clinical trials to find new drug candidates and expand the uses of its existing medicines.

Headquarters
Switzerland CH
Employees
12 000
IPO date
Mar 2, 2016
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue Research

Decided on BeOne Medicines? Get an email when BeOne Medicines AG reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one BeOne Medicines AG stock?

The intrinsic value for BeOne Medicines AG (6160) under the Base Case is HKD.

Is BeOne Medicines AG stock undervalued or overvalued?

Compared with the current market price of 247.4 HKD, the stock appears .

How reliable are our estimates? See how past valuations played out
Back to Top